Wasif M. Saif, MD | Authors


New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC

January 16, 2020

Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shares his expert opinion on the importance of the phase III IMbrave150 trial, which evaluated a targeted therapy combination in patients with hepatocellular carcinoma.